Table 1 Patient characteristics by arm
Characteristics | DA (n=402) | DClo (n=404) |
|---|---|---|
Age | ||
<60 | 8 | 8 |
60–64 | 115 | 116 |
65–69 | 168 | 168 |
70–74 | 89 | 89 |
75+ | 22 | 23 |
Median (range) | 67 (56–84) | 67 (56–80) |
Sex | ||
Female | 172 | 154 |
Male | 230 | 250 |
Diagnosis | ||
De novo | 289 | 290 |
Secondary | 69 | 71 |
High-risk MDS | 44 | 43 |
WBC (× 10 9 /l) | ||
<10 | 249 | 251 |
10–49.9 | 112 | 111 |
50–99.9 | 23 | 25 |
100+ | 18 | 17 |
Median | 4.1 (0.2–266.0) | 5.2 (0.2–336.7) |
Performance status | ||
WHO PS 0 | 250 | 250 |
WHO PS 1 | 130 | 130 |
WHO PS 2 | 13 | 16 |
WHO PS 3,4 | 9 | 8 |
Cytogenetics | ||
Favourable | 15 | 9 |
Intermediate | 229 | 228 |
Adverse | 67 | 77 |
Unknown | 91 | 90 |
Wheatley group | ||
Good | 129 | 112 |
Standard | 137 | 141 |
Poor | 136 | 151 |
FLT3-ITD | ||
Wild type | 101 | 97 |
Mutant | 14 | 18 |
Unknown | 287 | 289 |
NPM1 | ||
Wild type | 92 | 80 |
Mutant | 19 | 23 |
Unknown | 291 | 301 |
GO induction | ||
GO | 171 | 172 |
No GO | 170 | 170 |
Not randomised | 61 | 64 |
Consolidation | ||
2 courses | 68 | 63 |
3 courses | 70 | 62 |
Not randomised | 264 | 279 |
Maintenance | ||
Maintenance | 67 | 70 |
No maintenance | 70 | 67 |
Not randomised | 265 | 267 |
